Skip to content
Screener

Opko Health OPK Pharmaceutical — Cost of Goods Sold

Other segment segments

Diagnostics
$58.46M-29.0%

Similar metrics at other companies

Gyre Therapeutics, Inc. logo
GYREGyre Pharmaceuticals — Cost of Goods Sold
$2.21M+91.9%
Cal-Maine Foods logo
CALMPrepared Foods — Cost of Goods Sold
$46.34M+4,009%
Flexible Solutions International logo
FSICost of Goods Sold
$6.41M+16.0%
VenHub Global, Inc. logo
VHUBProduct Costs — Cost of Goods Sold
$64.15K
Barrett Business Services logo
BBSIBenefit Costs — Cost of Goods Sold
$28.92M+58.4%
Recursion Pharmaceuticals, Inc. logo
RXRXCost of Goods Sold
$11.49M-43.0%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$985.15M-2.3%
P/S1.7×+0.2×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Opko Health’s 10-Q, filed July 27, 2026.

Filed
Jul 27, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-318090
(In thousands) / Revenue from services: / PharmaceuticalFor the three months ended June 30, 2026 / —For the three months ended June 30, 2025 / —For the six months ended June 30, 2026 / —For the six months ended June 30, 2025 / —
Corporate
$46,090$14,963$60,058$27,229
Cost of revenue:
Pharmaceutical$25,101$25,022$47,399$47,836
Diagnostics58,46282,383114,604166,901
Corporate
$83,563$107,405$162,003$214,737
Gross margin:

Item 1. Financial Statements

FAQ

What is Opko Health's pharmaceutical — cost of goods sold?
Opko Health (OPK) reported pharmaceutical — cost of goods sold of $25.1M in Q2 2026.
How has Opko Health's pharmaceutical — cost of goods sold changed year-over-year?
Opko Health's pharmaceutical — cost of goods sold increased by 0.3% year-over-year, from $25.02M to $25.1M.
What is the long-term trend for Opko Health's pharmaceutical — cost of goods sold?
Over 2 years (2023 to 2025), Opko Health's pharmaceutical — cost of goods sold has grown at a -3.0% compound annual growth rate (CAGR), from $99.54M to $93.59M.
What does pharmaceutical — cost of goods sold mean?
The direct costs attributable to the production and delivery of pharmaceutical products and services. This includes raw materials, manufacturing labor, and overhead costs directly associated with generating pharmaceutical revenue.

Ask your AI about Opko Health's pharmaceutical — cost of goods sold.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude